136 related articles for article (PubMed ID: 22722453)
41. A genome landscape of SRSF3-regulated splicing events and gene expression in human osteosarcoma U2OS cells.
Ajiro M; Jia R; Yang Y; Zhu J; Zheng ZM
Nucleic Acids Res; 2016 Feb; 44(4):1854-70. PubMed ID: 26704980
[TBL] [Abstract][Full Text] [Related]
42. Effects of SRSF1 on subnuclear localization of topoisomerase I.
Girstun A; Ishikawa T; Staron K
J Cell Biochem; 2019 Jul; 120(7):11794-11808. PubMed ID: 30775805
[TBL] [Abstract][Full Text] [Related]
43. Effects of Alternative Splicing Events on Acute Myeloid Leukemia.
Chen SL; Dai YJ; Hu F; Wang Y; Li H; Liang Y
DNA Cell Biol; 2020 Nov; 39(11):2040-2051. PubMed ID: 32915082
[TBL] [Abstract][Full Text] [Related]
44. HNRNPA1, a Splicing Regulator, Is an Effective Target Protein for Cervical Cancer Detection: Comparison With Conventional Tumor Markers.
Kim YJ; Kim BR; Ryu JS; Lee GO; Kim HR; Choi KH; Ryu JW; Na KS; Park MC; So HS; Cho JH; Park DS
Int J Gynecol Cancer; 2017 Feb; 27(2):326-331. PubMed ID: 27984373
[TBL] [Abstract][Full Text] [Related]
45. Improving AML Classification Using Splicing Signatures.
Bowman TV
Clin Cancer Res; 2020 Jul; 26(14):3503-3504. PubMed ID: 32317289
[TBL] [Abstract][Full Text] [Related]
46. Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing.
Dolnik A; Engelmann JC; Scharfenberger-Schmeer M; Mauch J; Kelkenberg-Schade S; Haldemann B; Fries T; Krönke J; Kühn MW; Paschka P; Kayser S; Wolf S; Gaidzik VI; Schlenk RF; Rücker FG; Döhner H; Lottaz C; Döhner K; Bullinger L
Blood; 2012 Nov; 120(18):e83-92. PubMed ID: 22976956
[TBL] [Abstract][Full Text] [Related]
47. Splicing events in the control of genome integrity: role of SLU7 and truncated SRSF3 proteins.
Jiménez M; Urtasun R; Elizalde M; Azkona M; Latasa MU; Uriarte I; Arechederra M; Alignani D; Bárcena-Varela M; Álvarez-Sola G; Colyn L; Santamaría E; Sangro B; Rodriguez-Ortigosa C; Fernández-Barrena MG; Ávila MA; Berasain C
Nucleic Acids Res; 2019 Apr; 47(7):3450-3466. PubMed ID: 30657957
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of the clinical significance of global mRNA alternative splicing in patients with acute myeloid leukemia.
Yang YT; Yao CY; Chiu PJ; Kao CJ; Hou HA; Lin CC; Chou WC; Tien HF
Am J Hematol; 2023 May; 98(5):784-793. PubMed ID: 36855936
[TBL] [Abstract][Full Text] [Related]
49. Aberrant proteomic expression of NSRP70 and its clinical implications and connection to the transcriptional level in adult acute leukemia.
Choi DB; Park MR; Kim HR; Jun CD; Kim HJ; Shim H; Kim YD; Choi C; Choi KH; Yun KJ; Chae SC; Park R; Choe SK; Lee YJ; Park DS
Leuk Res; 2014 Oct; 38(10):1252-9. PubMed ID: 25176346
[TBL] [Abstract][Full Text] [Related]
50. Exploiting differential RNA splicing patterns: a potential new group of therapeutic targets in cancer.
Jyotsana N; Heuser M
Expert Opin Ther Targets; 2018 Feb; 22(2):107-121. PubMed ID: 29235382
[TBL] [Abstract][Full Text] [Related]
51. Physiological and Pathological Function of Serine/Arginine-Rich Splicing Factor 4 and Related Diseases.
Tan W; Wang W; Ma Q
Biomed Res Int; 2018; 2018():3819719. PubMed ID: 29789787
[TBL] [Abstract][Full Text] [Related]
52. Genome-wide identification of aberrant alternative splicing and RNA-binding protein regulators in acute myeloid leukaemia which may contribute to immune microenvironment remodelling.
Yang Y; Zhang YM; Wang Y; Liu K; Cui SY; Luo YQ; Zheng W; Xu J; Duan W; Wang JY
Carcinogenesis; 2023 Aug; 44(5):418-425. PubMed ID: 37209099
[TBL] [Abstract][Full Text] [Related]
53. Aberrant expression and regulatory network of splicing factor-SRSF3 in tumors.
Che Y; Fu L
J Cancer; 2020; 11(12):3502-3511. PubMed ID: 32284746
[TBL] [Abstract][Full Text] [Related]
54. The consensus sequence of FAMLF alternative splice variants is overexpressed in undifferentiated hematopoietic cells.
Chen WL; Luo DF; Gao C; Ding Y; Wang SY
Braz J Med Biol Res; 2015 Jul; 48(7):603-9. PubMed ID: 26083996
[TBL] [Abstract][Full Text] [Related]
55. Oncogene SRSF3 suppresses autophagy via inhibiting BECN1 expression.
Zhou L; Guo J; Jia R
Biochem Biophys Res Commun; 2019 Feb; 509(4):966-972. PubMed ID: 30654935
[TBL] [Abstract][Full Text] [Related]
56. Comprehensive Characterization of the Prognosis Value of Alternative Splicing Events in Acute Myeloid Leukemia.
Chen XX; Zhu JH; Li ZP; Xiao HT; Zhou H
DNA Cell Biol; 2020 Jul; 39(7):1243-1255. PubMed ID: 32543226
[TBL] [Abstract][Full Text] [Related]
57. Splicing machinery genomics events in acute myeloid leukaemia (AML): in search for therapeutic targets, diagnostic and prognostic biomarkers.
Dlamini Z; Shoba B; Hull R
Am J Cancer Res; 2020; 10(9):2690-2704. PubMed ID: 33042611
[TBL] [Abstract][Full Text] [Related]
58. Splicing Dysregulation as Oncogenic Driver and Passenger Factor in Brain Tumors.
Bielli P; Pagliarini V; Pieraccioli M; Caggiano C; Sette C
Cells; 2019 Dec; 9(1):. PubMed ID: 31861467
[TBL] [Abstract][Full Text] [Related]
59. [Aberrant RNA splicing and development of hematological malignancies].
Yoshimi A
Rinsho Ketsueki; 2020; 61(6):634-642. PubMed ID: 32624537
[TBL] [Abstract][Full Text] [Related]
60. Detection and targeting of splicing deregulation in pediatric acute myeloid leukemia stem cells.
van der Werf I; Mondala PK; Steel SK; Balaian L; Ladel L; Mason CN; Diep RH; Pham J; Cloos J; Kaspers GJL; Chan WC; Mark A; La Clair JJ; Wentworth P; Fisch KM; Crews LA; Whisenant TC; Burkart MD; Donohoe ME; Jamieson CHM
Cell Rep Med; 2023 Mar; 4(3):100962. PubMed ID: 36889320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
